RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor α

Oncogene

Volumn 31, Issue 4, 2012, Pages 527-534

  Huang, B ^a   Qu, Z ^b   Ong, C W ^c,d   Tsang, Y H N ^a,e   Xiao, G ^b   Shapiro, D ^a   Salto Tellez, M ^c,d   Ito, K ^f   Ito, Y ^d,e   Chen, L F ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^f NAGASAKI UNIVERSITY   (Japan)

Author keywords

Breast cancer; Degradation; ERa; RUNX3; Tumor suppressor

Indexed keywords

AGAR; ESTROGEN; ESTROGEN RECEPTOR ALPHA; TRANSCRIPTION FACTOR RUNX3;

AGAR DILUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER CELL; CANCER TISSUE; CARCINOGENICITY; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL TRANSFORMATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE TARGETING; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; LIQUID CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; SCID MOUSE; TRANSACTIVATION; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 3 SUBUNIT; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; PROTEASOME ENDOPEPTIDASE COMPLEX; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS; UBIQUITINATION;

MUS;

EID: 84856213379     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.252     Document Type: Article

References (28)

1. Anderson E. (2002). The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res 4: 197-201. (Pubitemid 34918998)
2. Cheskis BJ, Greger JG, Nagpal S, Freedman LP. (2007). Signaling by estrogens. J Cell Physiol 213: 610-617. (Pubitemid 350058252)
3. Chi XZ, Yang JO, Lee KY, Ito K, Sakakura C, Li QL et al. (2005). RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol Cell Biol 25: 8097-8107. (Pubitemid 41263003)
4. Duong V, Boulle N, Daujat S, Chauvet J, Bonnet S, Neel H et al. (2007). Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents. Cancer Res 67: 5513-5521. (Pubitemid 46997293)
5. Ekena K, Weis KE, Katzenellenbogen JA, Katzenellenbogen BS. (1996). Identification of amino acids in the hormone binding domain of the human estrogen receptor important in estrogen binding. J Biol Chem 271: 20053-20059. (Pubitemid 26281755)
6. Fan M, Nakshatri H, Nephew K.P. (2004). Inhibiting proteasomal proteolysis sustains estrogen receptor-alpha activation. Mol Endocrinol 18: 2603-2615. (Pubitemid 39482052)
7. Frech MS, Halama ED, Tilli MT, Singh B, Gunther EJ, Chodosh LA et al. (2005). Deregulated estrogen receptor alpha expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ. Cancer Res 65: 681-685. (Pubitemid 40216421)
8. Ito K, Inoue KI, Bae SC, Ito Y. (2009). Runx3 expression in gastrointestinal tract epithelium: resolving the controversy. Oncogene 28: 1379-1384.
9. Ito K, Lim AC, Salto-Tellez M, Motoda L, Osato M, Chuang LS et al. (2008). RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 14: 226-237.
10. Ito Y. (2004). Oncogenic potential of the RUNX gene family: 'overview'. Oncogene 23: 4198-4208. (Pubitemid 38765135)
11. Jerry DJ, Dunphy KA, Hagen MJ. (2010). Estrogens, regulation of p53 and breast cancer risk: a balancing act. Cell Mol Life Sci 67: 1017-1023.
12. Jiang Y, Tong D, Lou G, Zhang Y, Geng J. (2008). Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines. Pathobiology 75: 244-251. (Pubitemid 351918429)
13. Katzenellenbogen BS, Katzenellenbogen JA. (2000). Estrogen receptor transcription and transactivation: estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res 2: 335-344. (Pubitemid 32223616)
14. Khan SA, Rogers MA, Obando JA, Tamsen A. (1994). Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res 54: 993-997.
15. LaMarca HL, Rosen JM. (2007). Estrogen regulation of mammary gland development and breast cancer: amphiregulin takes center stage. Breast Cancer Res 9: 304-306.
16. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M et al. (2006). RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 66: 6512-6520. (Pubitemid 44085605)
17. Lonard DM, Nawaz Z, Smith CL, O'Malley BW. (2000). The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol Cell 5: 939-948.
18. Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW. (1999). Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci U S A 96: 1858-1862. (Pubitemid 29117832)
19. Reid G, Hubner MR, Metivier R, Brand H, Denger S, Manu D et al. (2003). Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol Cell 11: 695-707. (Pubitemid 36385123)
20. Sakuma A, Fukamachi H, Ito K, Ito Y, Takeuchi S, Takahashi S. (2008). Loss of Runx3 affects ovulation and estrogen-induced endometrial cell proliferation in female mice. Mol Reprod Dev 75: 1653-1661.
21. Shoker BS, Jarvis C, Clarke RB, Anderson E, Munro C, Davies MP et al. (2000). Abnormal regulation of the oestrogen receptor in benign breast lesions. J Clin Pathol 53: 778-783.
22. Subramaniam MM, Chan JY, Soong R, Ito K, Ito Y, Yeoh KG et al. (2009a). RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res Treat 113: 113-121.
23. Subramaniam MM, Chan JY, Yeoh KG, Quek T, Ito K, Salto-Tellez M. (2009b). Molecular pathology of RUNX3 in human carcinogenesis. Biochim Biophys Acta 1796: 315-331.
24. Tateishi Y, Kawabe Y, Chiba T, Murata S, Ichikawa K, Murayama A et al. (2004). Ligand-dependent switching of ubiquitin-proteasome pathways for estrogen receptor. EMBO J 23: 4813-4823. (Pubitemid 40069711)
25. Yamamura Y, Lee WL, Inoue K, Ida H, Ito Y. (2006). RUNX3 cooperates with FoxO3a to induce apoptosis in gastric cancer cells. J Biol Chem 281: 5267-5276. (Pubitemid 43847791)
26. Yan P, Fu J, Qu Z, Li S, Tanaka T, Grusby MJ et al. (2009). PDLIM2 suppresses human T-cell leukemia virus type I Tax-mediated tumorigenesis by targeting Tax into the nuclear matrix for proteasomal degradation. Blood 113: 4370-4380.
27. Yano T, Ito K, Fukamachi H, Chi XZ, Wee HJ, Inoue K et al. (2006). The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor beta-induced apoptosis. Mol Cell Biol 26: 4474-4488. (Pubitemid 43877568)
28. Zhang DH, Salto-Tellez M, Chiu LL, Shen L, Koay ES. (2003). Tissue microarray study for classification of breast tumors. Life Sci 73: 3189-3199. (Pubitemid 37237573)